Compounds > 9,10-dimethyl-1,2-benzanthracene
Page last updated: 2024-08-17

9,10-dimethyl-1,2-benzanthracene and fulvestrant

9,10-dimethyl-1,2-benzanthracene has been researched along with fulvestrant in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Huynh, H; Pollak, M; Yang, XF1
Chan, TW; Huynh, H; Mark, G1
Aoyagi, Y; Asao, T; Buzdar, AU; Hashimoto, A; Sato, K; Shibata, J; Terada, T; Wierzba, K; Yamamoto, Y; Yano, S; Yonekura, K1
Glazer, RI; Kopelovich, L; Lu, J; Yin, Y; Yuan, H1

Other Studies

4 other study(ies) available for 9,10-dimethyl-1,2-benzanthracene and fulvestrant

ArticleYear
A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780.
    Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 1996, Volume: 7, Issue:11

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Breast Neoplasms; Carcinogens; Carcinoma; Cell Division; Culture Media, Conditioned; Estradiol; Estrogen Antagonists; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 5; Mammary Neoplasms, Experimental; Oligonucleotides, Antisense; Rats; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured

1996
Induction of mammary epithelial cell differentiation and inhibition of dimethylbenz(A)anthracene-induced mammary tumour by co-administration of a pure antiestrogen ICI 182,780 and testosterone enanthate.
    International journal of oncology, 2001, Volume: 19, Issue:2

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Cell Differentiation; Cell Division; Drug Therapy, Combination; Epithelial Cells; Estradiol; Female; Fulvestrant; Immunohistochemistry; Ki-67 Antigen; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Rats; Rats, Sprague-Dawley; Testosterone; Time Factors

2001
TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jan-01, Volume: 11, Issue:1

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Oral; Animals; Carcinogens; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, Reporter; Humans; Luciferases; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Ovary; Protein Binding; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tamoxifen; Time Factors; Transcriptional Activation; Treatment Outcome; Uterus

2005
Drug-targeted inhibition of peroxisome proliferator-activated receptor-gamma enhances the chemopreventive effect of anti-estrogen therapy.
    Oncotarget, 2012, Volume: 3, Issue:3

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Anilides; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinogens; Carcinoma; Chemoprevention; Drug Synergism; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Mammary Neoplasms, Experimental; Mice; Microarray Analysis; Molecular Targeted Therapy; PPAR gamma

2012